Charles Richardson - Icosavax VP Operations
Insider
Charles Richardson is VP Operations of Icosavax
| Age | 72 |
| Phone | 206 737 0085 |
| Web | https://icosavax.com |
Icosavax Management Efficiency
The company has return on total asset (ROA) of (0.2673) % which means that it has lost $0.2673 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4223) %, meaning that it created substantial loss on money invested by shareholders. Icosavax's management efficiency ratios could be used to measure how well Icosavax manages its routine affairs as well as how well it operates its assets and liabilities.Icosavax currently holds 8.79 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Icosavax has a current ratio of 20.47, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Icosavax's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Justin Klee | Amylyx Pharmaceuticals | 34 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| MBA MD | Immix Biopharma | 49 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Christine CPA | Mereo BioPharma Group | 44 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Joshua Cohen | Amylyx Pharmaceuticals | 34 | |
| Gabriel BA | Immix Biopharma | 38 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| MS MBA | Inozyme Pharma | 48 | |
Management Performance
| Return On Equity | -0.42 | |||
| Return On Asset | -0.27 |
Icosavax Leadership Team
Elected by the shareholders, the Icosavax's board of directors comprises two types of representatives: Icosavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icosavax. The board's role is to monitor Icosavax's management team and ensure that shareholders' interests are well served. Icosavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icosavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Bekiroglu, General Secretary | ||
| Neil King, Chair CoFounder | ||
| Jennifer Raymond, Senior Operations | ||
| Ami MPH, Senior Affairs | ||
| Mr MPH, Chief Officer | ||
| Niranjan MD, Chief Officer | ||
| Cassia Cearley, Treasurer Officer | ||
| Charles Richardson, VP Operations | ||
| Thomas CFA, Chief Officer | ||
| Lori Stewart, Senior Culture | ||
| Adam Simpson, CEO and President | ||
| David Baker, Cofounder Board | ||
| David MD, Cofounder Board |
Icosavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icosavax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 547.9 M | |||
| Shares Outstanding | 50.23 M | |||
| Shares Owned By Insiders | 3.47 % | |||
| Shares Owned By Institutions | 87.64 % | |||
| Number Of Shares Shorted | 321.31 K | |||
| Price To Earning | 63.56 X | |||
| Price To Book | 3.31 X | |||
| Price To Sales | 153.31 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Icosavax Stock
If you are still planning to invest in Icosavax check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Icosavax's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |